Applied Therapeutics (APLT)
(Real Time Quote from BATS)
$6.14 USD
0.00 (0.00%)
Updated Aug 28, 2024 01:10 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Applied Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 50 | 31 | 81 | 97 | 39 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 7 | 8 | 6 | 7 |
Total Current Assets | 54 | 37 | 88 | 103 | 46 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 55 | 38 | 90 | 105 | 48 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 9 | 1 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 15 | 17 | 20 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 54 | 14 | 0 | 0 | 0 |
Total Current Liabilities | 71 | 33 | 26 | 21 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 72 | 34 | 27 | 23 | 16 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 451 | 353 | 329 | 243 | 99 |
Retained Earnings | -469 | -349 | -266 | -161 | -67 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -17 | 4 | 63 | 82 | 33 |
Total Liabilities & Shareholder's Equity | 55 | 38 | 90 | 105 | 48 |
Total Common Equity | -17 | 4 | 63 | 82 | 33 |
Shares Outstanding | 84.80 | 48.00 | 26.20 | 22.40 | 21.60 |
Book Value Per Share | -0.20 | 0.08 | 2.39 | 3.66 | 1.51 |
Fiscal Year End for Applied Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 122 | 146 | 50 | 37 | 36 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 4 | 4 | 7 | 7 |
Total Current Assets | 128 | 151 | 54 | 44 | 43 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 128 | 151 | 55 | 45 | 44 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 2 | 6 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 15 | 15 | 12 | 16 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 42 | 65 | 54 | 37 | 26 |
Total Current Liabilities | 55 | 84 | 71 | 56 | 47 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 55 | 84 | 72 | 56 | 48 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 622 | 620 | 451 | 420 | 384 |
Retained Earnings | -550 | -553 | -469 | -431 | -389 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 72 | 67 | -17 | -11 | -4 |
Total Liabilities & Shareholder's Equity | 128 | 151 | 55 | 45 | 44 |
Total Common Equity | 72 | 67 | -17 | -11 | -4 |
Shares Outstanding | 114.20 | 114.20 | 84.80 | 63.10 | 57.80 |
Book Value Per Share | 0.63 | 0.59 | -0.20 | -0.17 | -0.07 |